Rivoceranib

Phase 3Small molecule

EElevar Therapeutics

Rivoceranib is one of 141 small molecule programs targeting Adenoid Cystic Carcinoma. It is currently in Phase 3.

Indications

Total Trials

Active Trials

140

Competitors

Pipeline

Status by Indication[3][1]

Indication

Adenoid Cystic CarcinomaActive, not recruiting

Metastatic Colorectal CancerActive, not recruiting

Olfactory NeuroblastomaActive, not recruiting

Hepatocellular CarcinomaActive, not recruiting

Gastric CancerActive, not recruiting

CholangiocarcinomaActive, not recruiting

Adenoid Cystic CarcinomaPhase 2

Active, not recruiting

Metastatic Colorectal CancerPhase 1

Active, not recruiting

Olfactory NeuroblastomaPhase 2

Active, not recruiting

Hepatocellular CarcinomaPreclinical

Active, not recruiting

Gastric CancerPhase 3

Active, not recruiting

CholangiocarcinomaPhase 2

Active, not recruiting

Competition

Competitive Landscape

797 competitors in Hepatocellular Carcinoma

#DrugCompanyPhaseTrials

Rivoceranib

EElevar Therapeutics

Phase 3

3 2

Cysteine Hydrochloride

Novartis

Preclinical

1 3

Viread

Gilead

Preclinical

1 4

Sovaldi

Gilead

Preclinical

1 5

Hepsera

Coreg

2 7

Doptelet

AAkarx

Preclinical

1 8

Opdivo

Bristol-Myers Squibb

Preclinical

2 9

PD-1 Inhibitor

Johnson & Johnson

Preclinical

2 10

Statin

Bristol-Myers Squibb

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2026

Phase 3Active, not recruiting

Hepatocellular Carcinoma

NCT04639180

Q4 2026

Phase 2Not yet recruiting

Thymic Epithelial Tumor

NCT06200233

Q3 2028

Phase 2Recruiting

Cholangiocarcinoma

NCT07105748

Not yet recruiting

Hepatocellular Carcinoma

NCT07147101

Clinical

Trials by Indication[1]

Hepatocellular Carcinoma3 trials

Different First-line Immunotherapy for Advancer Hepatocellular Carcinoma: A Prospective Observational Study on Efficacy and Immune Microenvironment

Not yet recruiting·FFudan University··NCT07147101·150 enrolled

A Study of Camrelizumab Combined With Rivoceranib Mesylate Versus Investigator's Choice of Regimen in Treatment of Patients With Advanced Hepatocellular Carcinoma (HCC)

Terminated·JJiangsu HengRui Medicine Co., Ltd.·Phase 3·NCT04985136·1 enrolled

A Study to Evaluate Camrelizumab Plus Rivoceranib (Apatinib) as Adjuvant Therapy in Patients With Hepatocellular Carcinoma (HCC) at High Risk of Recurrence After Curative Resection or Ablation

Active, not recruiting·JJiangsu HengRui Medicine Co., Ltd.·Phase 3·NCT04639180·687 enrolled

Gastroesophageal Junction Cancer1 trial

A Study to Evaluate Safety, Tolerability, and Efficacy Profile of Rivoceranib With Paclitaxel in Advanced Gastric or Gastroesophageal Junction Cancer

Terminated·EElevar Therapeutics·Phase 1/2·NCT03707028·12 enrolled

Olfactory Neuroblastoma1 trial

A Phase II Study of Rivoceranib for Patients With Recurrent or Metastatic Olfactory Neuroblastoma

Withdrawn·MM.D. Anderson Cancer Center·Phase 2·NCT06308575

Adenoid Cystic Carcinoma1 trial

A Study to Evaluate the Efficacy and Safety of Rivoceranib in Participants With Recurrent or Metastatic Adenoid Cystic Carcinoma (ACC)

Terminated·EElevar Therapeutics·Phase 2·NCT04119453·80 enrolled

Cholangiocarcinoma1 trial

HAIC Combined With Camrelizumab Plus Rivoceranib for Advanced Mixed Hepatocellular-cholangiocarcinoma (HCC-CCA)

Recruiting·FFudan University·Phase 2·NCT07105748·45 enrolled

4 more indications

ART1 trial

A Study Comparing Four Different Rivoceranib Tablets in Healthy Participants

Completed·EElevar Therapeutics·Phase 1·NCT05287360·60 enrolled

Thymic Epithelial Tumor1 trial

Rivoceranib in Patients With Metastatic Thymic Epithelial Tumor

Not yet recruiting·SSamsung Medical Center·Phase 2·NCT06200233·40 enrolled

Gastric Cancer1 trial

A Study to Evaluate Rivoceranib Plus Best Supportive Care Compared to Placebo Plus Best Supportive Care in Participants With Gastric Cancer

Completed·EElevar Therapeutics·Phase 3·NCT03042611·460 enrolled

Metastatic Colorectal Cancer1 trial

A Study of Rivoceranib and Trifluridine/Tipiracil for Metastatic Colorectal Cancer (mCRC)

Terminated·EElevar Therapeutics·Phase 1·NCT04073615·29 enrolled

Sources

References

[1]
ClinicalTrials.gov — 11 trial records for Rivoceranib. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Rivoceranib compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Rivoceranib. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Elevar Therapeutics company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: EElevar Therapeutics

Rivoceranib

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2026

Q4 2026

Q3 2028

Trials by Indication[1]

Hepatocellular Carcinoma3 trials

Gastroesophageal Junction Cancer1 trial

Olfactory Neuroblastoma1 trial

Adenoid Cystic Carcinoma1 trial

Cholangiocarcinoma1 trial

ART1 trial

Thymic Epithelial Tumor1 trial

Gastric Cancer1 trial

Metastatic Colorectal Cancer1 trial

References

Drug Info

Quick Facts

Related News